Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: August 2010

45 - Thrombophilia and Implanation Failure

from PART III - ASSISTED REPRODUCTION

Summary

This chapter focuses on the association between acquired and inherited thrombophilia and implantation failure (IF). The pathogenesis of recurrent IF in patients with thrombophilic gene mutation may involve the effect of hypofibrinolysis on trophoblast migration. Trophoblastic migration and invasion during implantation involve extracellular matrix degradation, which is facilitated by matrix metalloproteinases (MMP). Recently, a variety of pathogenetic mechanisms have been suggested to explain the prothrombotic effect of antiphospholipid antibody (APA), the main cause of acquired thrombophilia. Recently, it has been suggested that APA may negatively impact the transformation of the endometrium into decidua, creating a hostile environment for blastocyst implantation. The chapter investigates the main therapeutic modalities such as heparin, aspirin (ASA), corticosteroids, and intravenous immunoglobulin alone or in combinations for treatment of IF. It is premature to recommend anticoagulation for patients with thrombophilia and IF.
REFERENCES
Robert, CJ, Lowe, Cr. Where have all the conceptions gone?Lancet 1975; I: 498–9.
ZinMn, MJ, O'Connor, J, Clegg, ED et al. Estimates of human fertility and pregnancy loss. Fertil Steril 1996; 65: 503–9.
Christiansen, OB, Nielsen, H, Kolte, A. Future directions of failed implantation and recurrent miscarriage research.
Assisted reproductive technology in the United States: 2000 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril 2004; 81(5): 1207–20.
Macklon, NS, Geraedts, JPM, Fauser, BCJM. Conception to ongoing pregnancy: the ‘black box’ of early pregnancy loss. Hum Reprod Update 2002; 8: 333–43.
Vaquero, E, Lazzrin, N, Caserta, D et al. Diagnostic evaluation of women experiencing repeated in vitro fertilization failure. Eur J Obstet Gynecol 2005.
Clark, DA, Coulam, CB, Daya, S et al. Unexplained sporadic and recurrent miscarriage in the new millennium: a critical analysis of immune mechanisms and treatments. Hum Reprod Update 2001; 7: 501–11.
Gianaroli, L, Masgli, C, Ferraretti, AP et al. Preimplantation diagnosis for aneuploidies in patients undergoing in vitro fertilization with a poor prognosis: identification of the categories for which it should be proposed. Fertil Steril 1999; 72: 837–44.
Coulam, CB, Roussev, RG. Correlation of NK cell activation and inhibition markers with NK cytotoxicity among women experiencing immunological implantation failure after in vitro fertilization and embryo transfer. J Assist Reprod Genet 2003; 20: 58–62.
Ntrivalas, EI, Kwak-Kim, JYH, Gilman-Sachs, A et al. Status of peripheral blood natural killer cells in women with recurrent spontaneous abortions and infertility of unknown aetiology. Hum Reprod 2001; 16: 855–61.
Michou, VI, Kanavaros, P, Athanasssiou, V et al. Fraction of the peripheral blood concentration of CD56+/CD16-/CD3- cells in total natural killer cells as an indication of fertility and infertility. Fertil Steril 80: 691–7.
Roussev, FR, Kaider, BD, Price, et al. Laboratory evaluation of women experiencing reproductive failure. Am J Reprod Immunol 1996; 35: 415–20.
Kaider, AS, Kaider, BD, Janowicz, PB et al. Immunodiagnostic evaluation in women with reproductive failure. Am J Reprod Immunol 1999; 42: 335–46.
Christiansen, O, Nielsen, H, Kolte, A. Future directions of failed implantation and recurrent miscarriage research. Reprod Biomed Online 2006; 13(1): 71–83.
Kupferminc, MJ, Eldor, A, Steinman, N et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Eng J Med 1999; 340: 9–13.
Hakim, RB, Gray, RH, Zacur, H. Infertility and early pregnancy loss. Am J Obstet Gynecol 1995; 172(5): 1510–17.
Cauchi, MN, Coulam, CB, Cowchock, S et al. Predictive factors in recurrent spontaneous aborters—a multicenter study. Am J Reprod Immunol 1995; 33: 165–70.
Seligsohn, U, Lubetski, A. Genetic susceptibility to venous thrombosis. N Eng J Med 2001; 344: 1222–30.
Dahlback, B, Hildebrand, B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396–400.
Rodeghiero, F, Tosetto, A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643–50.
Kalafatis, M, Bertina, RM, Rand, MD, Mann, KG. Characterization of the molecular defect in factor VR506Q. J Biol Chem 1995; 270: 4053–7.
Camire, RM, Kalafatis, M, Cushman, M, Tracy, RP, Mann, KG, Tracy, PB. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem 1995; 270: 20794–800.
Lee, DH, Henderson, PA, Blajchman, MA. Prevalence of factor V Leiden in a Canadian blood donor population. CMAJ 1996; 155: 285–9.
Ridker, PM, Hennekens, CH, Lindpaintner, K, Stampfer, MJ, Eisenberg, PR, Milletich, JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infraction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912–17.
Salomon, O, Steinberg, DM, Zivelin, A, Gitel, S, Dardik, R, Rosenberg, N et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511–18.
Ridker, PM, Miletich, JP, Hennekens, CH, Buring, JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277: 1305–7.
Dulicek, P, Maly, J, Safarova, M. Risk of thrombosis in patients homozygous and heterozygous forfactro V Leiden in the East Bohemian region. Clin Appl Thromb Hemost 2000; 6: 87–9.
Poort, SR, Rosendaal, FR, Reitsma, PH, Bertina, RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–703.
Rosendaal, FR, Doggen, CJ, Zivelin, A, Arruda, VR, Aiach, M, Siscobick, DS et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706–8.
Egberg, O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516–30.
Martinelli, I, Mannucci, PM, Stefano, V, Taioli, E, Rossi, B, Crosti, F et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92: 2353–8.
Mateo, J, Oliver, A, Borrell, M, Sala, N, Fontcuberta, J. Laboratory evaluation and clinical characteristics of 2.132 consecutive unselected patients with venous thromboembolism—results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77: 444–51.
Griffin, JH, Evatt, B, Zimmerman, TS, Kleiss, AJ, Wideman, C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370–3.
Ben-Tal, O, Zivelin, A, Seligsohn, U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61: 50–4.
Tait, RC, Walker, ID, Reitsma, PH, Islam, SI, McCall, F, Poort, SR et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73: 87–93.
Sakata, T, Kario, K, Katayama, Y, Matsuyama, T, Kato, H, Miyata, T. Studies on congenital protein C deficiency in Japanese: prevalence, genetic analysis, and relevance to the onset of arterial occlusive diseases. Semin Thromb Hemost 2000; 26: 11–16.
Pabinger, I, Brucker, S, Krle, PA, Schneider, B, Korninger, HC, Neissner, H et al. Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patients screening. Blood Coagul Fibrinolysis 1992; 3: 547–53.
Comp, PC, Nixon, RR, Cooper, MR, Esmon, CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74: 2082–8.
Comp, PC, Esmon, Ct. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525–8.
Gladson, CL, Sharrer, I, Hach, V, Beck, KH, Griffin, JH. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988; 59: 18–22.
Goyette, P, Frosst, P, Rosenblatt, DS, Rozen, R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet 1995; 56: 1052–9.
Mudd, SH, Skovby, F, Levy, HL, Pettigrew, KD, Wilcken, B, Pyeritz, RE et al. The natural history of homocysteinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37: 1–31.
Jacques, PF, Bostom, AG, Williams, RR, Ellison, RC, Eckfeldt, JH, Rosenberg, IH et al. Relation between folate status, a common mutation in the methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7–9.
Kluijtmans, , Heuvel, LP, Boers, GH, Frosst, P, Stevens, EM, Oost, BA et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35–41.
Cattaneo, M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999; 81: 165–76.
Ray, JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998; 158: 2101–6.
Bick, RL. Antiphospholipid thrombosis syndromes. Hematol Oncol Clin North Am 2003; 17: 115.
Bick, RL, Baker, WF. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 1999; 25: 333.
Coulam, DB, Jeyendran, RS, Fishel, , Roussev, R. Reprod Biomed Online 2006; 12(3): 322–7.
Rawlins, ND, Barrett, AJ et al. Evolutionary families of peptidases. Biochem J 1993; 290: 205–18.
Axelrod, HR. Altered trophoblast functions in implantation-defective mouse embryos. Dev Biol 1985; 108: 185–90.
Many, A, Schrieber, L, Rosner, S et al. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol 2001; 1041–4.
Chung, HW, Wen, Y, Ahn, JJ et al. Interluekin-1 beta regulates urokinase plasminogen activator (u-PA), u-PA receptor, soluble u-PA receptor, and plasminogen activator inhibitor-1 messenger ribonucleic acid expression in cultured human endometrial stromal cells. J Clin Endocrinol 2001; 86: 1332–40.
Aflalo, ED, Sod-Moriah, UA, Patashnik, G, Har-Vardi, I. Differences in the implantation rates of rat embryos developed in viva and in vitro: possible role from plasminogen activators. Fertil Steril 2004; 1: 780–5.
Solberg, H, Rinkenberger, J, Dano, K et al. A functional overlap of plasminogen and MMPs regulates vascularization during placental development. Development 2003; 130: 4439–50.
Gopel, W, Ludwig, M, Junge, A et al. Selection pressure for the factor-V Leiden mutation and embryo implantation. Lancet 2001; 358: 1238–9.
Rand, JH, Wu, XX, Quinn, AS et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Path 2003; 163: 1193–200.
Amengual, O, Atsumi, T, Khamashta, MA. Tissue factor in antiphospholipid syndrome: shifting the focus from coagulation to endothelium. Rheumatology 2003; 42: 1029–31.
Out, HJ, Bruinse, HW, Derksen, RH. Anti-phospholipid antibodies and pregnancy loss. Hum Reprod 1999; 6: 889–97.
Salafia, CM, Cowchock, FS. Placental pathology and antiphospholipid antibodies: a descriptive study. Am J Perinatol 1997; 14: 435–41.
Horn, JT, Crave, C, Ward, K. Features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta 2004; 25: 642–8.
James, JL, Stone, PR, Chamley, LW. The regulation of trophoblast differentiation by oxygen in the first trimester of pregnancy. Hum Reprod update 2006; 12: 137–44.
Shurtz-Swirski, R, Inbar, O, Blank, M et al. In vitro effect of anticardiolipin autoantibodies upon total and pulsatile placental hCG secretion during early pregnancy. Am J Reprod Immunol 1993; 29: 206–10.
Adler, RR, Ng, AK, Rote, NS. Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR. Biol Reprod 1995; 53: 905–10.
Di Simone, N, Carolis, S, Lanzone, A et. In vitro effect of antiphospholipid antibody-containing sera on basal and gonadotrophin releasing hormone-dependent human chorionic gonadotrophin release by cultured trophoblast cells. Placenta 1995; 16: 75–83.
Di Simone, N, Meroni, PL, Papa, N et al. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered B2-glycoprotein I. Arthritis Rheum 2000; 43: 140–50.
Chamley, LW, Duncalf, A, Mitchell, M et al. Action of anticardiolipin and antibodies to B2 glycoprotein I on trophoblast proliferation as a mechanism for fetal death. Lancet 1998; 352: 1037–8.
Mak, IY, Brosens, JJ, Christian, M et al. Regulated expression of signal transducer and activator of transcription, Stat5, and its enhancement of PRL expression in human endometrial stromal cells in vitro. J Clin Endocrinol Metab 2002; 87: 2581–8.
Rouby, RA, Hoffman, M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet 1997; 350: 1491–2.
Qublan, HS, Eid, SS, Ababneh, HA, Amarin, ZO, Al-Khafaji, FF, Khader, YS. Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum Reprod 2006; 21(10): 2694–8.
Grandone, E, Colaizzo, D, Lo Bue, A, Checola, MG, Cittadini, E, Margaglione, M. Inherited thrombophilia and in vitro fertilization implantation failure. Fertil Steril 2001; 76(1): 201–2.
Martinelli, I, Taioli, E, Ragni, G, Levi-Setti, P, Passomonti, SM, Battaglioli, T, Lodigiani, C, Mannucci, PM. Embryo implantation after assisted reproductive procedures and maternal thrombophilia. Haematologica 2003; 88(7): 789–93.
Azem, F, Many, F, Yovel, I, Amit, A, Lessing, J, Kupferminc, M. Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod 2004; 19(2): 368–74.
Coulam, C, Jeyendran, RS, Fishel, L, Roussev, R. Multiple thrombophilic gene mutations are risk factors for implantation failure. Reprod Biomed Online 2006; 12(3): 322–7.
Dunne, FM, Doggen, CJM, Heemskerk, M, Rosendall, FR, Helmerhorst, FM. Factor V Leiden mutation in relation to fecundity and miscarriage in women with venous thrombosis. Hum Reprod 2005; 20(3): 802–6.
Gopel, W, Ludwig, M, Junge, A, Kohlmann, T, Diedrich, K, Moller, J. Selection pressure for the factor-V-Leiden mutation and embryo implantation. Lancet 2001; 358: 1238–9.
Hornstein, M, Davis, O, Massey, J, Paulson, R, Collins, J. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis. Fertil Steril 2000; 73(2): 330–3.
McIntyre, JA. Antiphospholipid antibodies in implantation failure. Am J Reprod Immunol 2003; 49: 221–9.
Matsubayashi, H, Arai, T, Izumi, S, Sugi, T, McIntyre, J, Makino, T. Anti-annexin V antibodies in patients with early pregnancy loss or implantation failures. Fertil Steril 2001; 76(4): 694–9.
Stern, C, Chamley, L, Hale, L, Kloss, M, Speirs, A, Baker, HW. Antibodies to B2 glycoprotein I are associated with in vitro fertilization implantation failure as well as recurrent miscarriage: results of a prevalence study. Fertil Steril 1998; 70(5): 938–44.
Gleicher, N, Vidali, A, Karande, V. The immunological ‘war of the roses’: disagreements amongst reproductive immunologists. Hum Reprod 2002; 17: 539–42.
Stern, C, Chamley, L, Norris, H, Hale, L, Baker, HW. A randomized, double-blind, placebo controlled trial of heparin and aspirin for women with fertilization implantation failure and antiphospholipid or antinuclear antibodies. Fertil Steril 2004; 81(5): 376–83.
Kutteh, WH, Yetman, DL, Chantilis, SJ, Crain, J. Effect of antiphospholipid antibodies in women undergoing in-vitro fertilization: role of heparin and aspirin. Hum Reprod 1997; 12(6): 1171–5.
Sher, G, Feinman, M, Zouves, C, Duttner, G, Maassarani, G, Salem, R, Matzner, W, Ching, W, Chong, P. High fecundity rates following in-vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Hum Reprod 1994; 9(12): 2278–83.
Fiedler, K, Wurfel, W. Effectivity of heparin in assisted reproduction. Eur J Med Res 2004; 9(4): 207–14.
Sher, G, Zouves, C, Geinman, M, Maassarani, G, Matzner, W, Chong, P, Ching, W. A rational basis for the use of combined heparin/aspirin and IVIG immunotherapy in the treatment of recurrent IVF failure associated with antiphospholipid antibodies. Am J Reprod Immunol 1998; 39(6): 391–4.
Taniguchi, F. Results of prednisolone given to improve the outcome of in vitro fertilization-embryo transfer in women with antinuclear antibodies. J Reprod Med 2005; 50(6): 383–8.
Sher, G, Matzner, W, Feinman, M, Maassarani, G, Zouves, C, Chong, P, Ching, W. The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. Am J Reprod Immunol 1998; 40(2): 74–82.
Rosenberg, RD, Edelberg, J, Zhang, L. The heparin/antithrombin system: a natural anticoagulant mechanism. In: Colman, RW, Hirsh, J, Marder, VJ, Clowes, AW, George, JN, Eds. Thrombosis and Hemostasis: Basic Principles and Clinical Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001: 711–31.
Di Simone, N, Ferrazzani, S, Castellani, R, Carolis, S, Mancuso, S, Caruso, A. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Hum Reprod 1997; 12(9): 2061–5.
Bose, P, Black, S, Dadyrov, M, Weissebborn, U, Neulen, J, Regan, L, Huppertz, B. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol 2005; 192(1): 23–30.
Hasegawa, I, Yamanoto, Y, Suzuki, M, Murakawa, H, Kuraboyashi, T, Takakuwa, K, Tanaka, K. Prednisolone plus low-dose aspirin improves the implantation rate in women with automimmune conditions who are undergoing in vitro fertilization. Fertil Steril 1998; 70(6): 1044–8.
Ando, T, Suganuma, N, Furuhashi, M, Asada, Y, Kondo, I, Tomoda, Y. Successful glucocorticoid treatment for patients with abnormal autoimmunity on in vitro fertilization and embryo transfer. J Assist Reprod Genet 1996; 13(10): 776–81.
Taniguchi, F. Results of prednisolone given to improve the outcome of in vitro fertilization-embryo transfer in women with antinuclear antibodies. J Reprod Med 2005; 50(6): 383–8.
Sher, G, Matzner, W, Feinman, M, Maassarani, G, Zouves, C, Chong, P, Ching, W. The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G in the management of antiphospholipid antibody positive women undergoing in vitro fertilization. Am J Reprod Immunol 1998; 40(2): 74–82.
Rizk, B, Abdalla, HI. In Vitro fertilization. In: Rizk, B, Abdalla, HI, Eds. Infertility and assisted reproductive technology. 2008; chapter 9, 116–118.